top of page
NEOK Bio About Us 2_edited.jpg

Forging Cancer Breakthroughs in a New Era Of Knowledge

At NEOK Bio, we’re dedicated to transforming the treatment of cancer, harnessing the boundless potential of scientific innovation to solve therapeutic challenges and improve patient outcomes.

Fulfilling the Promise of Bispecific Antibody Drug Conjugates

Backed by ABL Bio, a world-leader in antibody engineering, NEOK is at the forefront of cutting-edge innovation in antibody drug conjugates (ADCs). We’re rapidly advancing a pipeline of differentiated bispecific ADCs that unleash the power of the ADC modality to treat cancer in ways never before possible.

NeokBio_ADCBispecific_R7.png

Our leadership team brings together decades of oncology drug development expertise and a proven track record in ADC innovation. United by a shared vision, our world class team is pioneering a dual-targeting approach which could become the cornerstone of precision medicine for cancer patients.

NEOK Dark Grain Background.jpg

Our Science

Our scientific approach aims to overcome the limitations of conventional ADCs, using a dual-targeting strategy with the potential for improved safety and efficacy in the treatment of solid tumor cancers with unmet needs.

GettyImages-1413600685.jpg
NEOK Bio Cancer Treatment_edited.jpg
NEOK Dark Grain Background.jpg

Our Pipeline

We’re rapidly advancing a novel pipeline of bispecific ADCs for clinically validated targets, while balancing high-expression, selectivity, and target-related safety signals.

bottom of page